Pleiotropy and variable expressivity describe different observations about the same mutation, and Step 1 exploits the fact that students confuse them. Pleiotropy means one gene mutation produces effects across multiple, seemingly unrelated organ systems — it describes the breadth of a gene's reach. Variable expressivity means the same mutation produces different severity between different individuals — it describes the variation in how strongly the gene is expressed. A disease like NF1 demonstrates both simultaneously, which is precisely why it is a favorite trap.
The common mistake
In a deepen-wave open-ended probe, Maya was asked to describe what is happening in a scenario involving two NF1 patients: one with hundreds of neurofibromas, plexiform tumors, and an optic glioma; the other with just two café-au-lait spots and no tumors. Both have the same mutation. NF1 has nearly 100% penetrance.
Maya's answer: "this is due to pleiotropy."
The correction the tutor gave is precise and worth understanding: pleiotropy is in the scenario, but it describes something else. Pleiotropy is why NF1 hits skin, nerves, eyes, and vasculature from a single NF1 mutation — one gene, multiple organ systems. That is the breadth of the gene's reach across tissues.
The question was specifically about two different patients with the same mutation looking completely different from each other — one mild, one severe. That observation is variable expressivity: the same gene expressed to different degrees between individuals.
NF1 demonstrates both at once. Pleiotropy explains why any NF1 patient has findings in multiple systems. Variable expressivity explains why two NF1 patients have such different severity profiles. Calling the whole scenario "pleiotropy" misses the second half — and misses the term Step 1 actually wants for the between-patient comparison.
A lot of students reach for pleiotropy when they see a multi-system disease. It feels right because multi-system = many effects = pleiotropy. The trap is that "two patients with different severity" is a different observation that requires a different term.
The actual mechanism
These are definitional distinctions, so precision matters.
Pleiotropy is a property of the gene itself: one gene influences multiple, apparently unrelated biological processes. FBN1 mutations in Marfan syndrome disrupt fibrillin in eyes, aorta, and skeletal tissue — three systems, one gene. NF1 mutations disrupt neurofibromin (a RAS-GAP) in nerves, skin, eyes, vasculature, and bone. The clinical consequence of one gene being expressed across many tissue types is that patients develop findings in multiple, seemingly unrelated places. The organ systems are not unrelated at the molecular level — they all depend on that one protein — but at the clinical level, the phenotype looks scattered.
Variable expressivity is a property of how the same mutation manifests between individuals. It is measured between people, not between organ systems. Two patients with the same BRCA1 mutation — one develops breast cancer at 34, the other at 62 — are showing variable expressivity. Two NF1 patients with the same mutation — one with extensive tumor burden, one with minimal café-au-lait spots — are showing variable expressivity. Nuclear modifier genes, environmental factors, and stochastic events in development all contribute to why the same mutation produces different severity in different people.
Incomplete penetrance is a third concept that often appears in the same vignette. Penetrance asks whether the gene is expressed at all — a binary question about presence or absence of the phenotype. NF1 has nearly 100% penetrance, so almost all mutation carriers show some clinical finding. But the degree of those findings varies — that is expressivity, not penetrance. A father carrying an NF1 mutation with zero symptoms despite nearly 100% population penetrance would be the rare incomplete penetrance case. A father with mild symptoms and a child with severe disease — same mutation, different severity — is variable expressivity.
The synthesis question from Maya's session required all three terms unprompted. A patient with NF1 has seizures, café-au-lait spots, and an optic glioma — pleiotropy. His sister has the same mutation but only two café-au-lait spots — variable expressivity. Their father carries the mutation with zero symptoms — incomplete penetrance. Maya produced all three labels correctly in that final synthesis, after working through the NF1 confusion earlier in the session.
For the heteroplasmy distinction: when variable severity appears in a maternal inheritance pattern, the mechanism is not variable expressivity — it is heteroplasmy. The surface appearance of "same mutation, different severity" is identical, but the biology is entirely different.
How to remember it
Two contrast pairs:
- Pleiotropy = one gene, many systems (breadth across organ systems)
- Variable expressivity = same gene, different severity between individuals (depth varies between people)
The NF1 test: "Why does it hit skin, nerves, and eyes?" → pleiotropy. "Why is one patient mild and another severe?" → variable expressivity.
Check yourself
A woman with Marfan syndrome has lens dislocation, aortic root dilation, and tall stature with long fingers. Her brother has the same FBN1 mutation but only mild aortic root dilation and no lens or skeletal findings. Their mother carries the mutation with no detectable clinical features.
Which genetic concepts best explain each of the following observations?
- The woman has findings in eyes, vasculature, and skeleton
- The woman is severely affected while her brother has only a mild aortic finding
- The mother carries the mutation with no clinical features
A) 1 = variable expressivity; 2 = pleiotropy; 3 = incomplete penetrance
B) 1 = incomplete penetrance; 2 = variable expressivity; 3 = pleiotropy
C) 1 = pleiotropy; 2 = variable expressivity; 3 = incomplete penetrance
D) 1 = pleiotropy; 2 = incomplete penetrance; 3 = variable expressivity
C. Multi-system effects from one FBN1 mutation = pleiotropy (1). Same mutation, different severity between siblings = variable expressivity (2). Mutation carrier with zero clinical features = incomplete penetrance (3). The distractor in option A reverses pleiotropy and variable expressivity — the most common mistake.
Close the gap
The moment in Maya's session that surfaced the pleiotropy/expressivity confusion was not a multiple-choice question — it was an open-ended probe where she had to produce the terms herself. That is harder than recognizing them in a list, and it is closer to what Step 1 actually demands under pressure. Gradual Learning's tutor runs that kind of probe as standard.